Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15020549
Abstract: Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed… read more here.
Keywords: fexuprazan; aspirin induced; pharmacodynamic pharmacokinetic; novel potassium ... See more keywords
Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v28.i44.6294
Abstract: BACKGROUND Fexuprazan, a novel potassium-competitive acid blocker, reversibly suppresses the K+/H+-ATPase enzyme in proton pumps within gastric parietal cells. Fexuprazan’s suppression of gastric acid was maintained in healthy individuals for 24 h in a dose-dependent… read more here.
Keywords: erosive esophagitis; safety; fexuprazan; efficacy safety ... See more keywords
Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis.
Sign Up to like & getrecommendations! Published in 2023 at "Gut and liver"
DOI: 10.5009/gnl220457
Abstract: Background/Aims Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in… read more here.
Keywords: chronic gastritis; fexuprazan; efficacy; acute chronic ... See more keywords